<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2025-28-22-26</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-4721</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Сравнение анамнестических и лабораторных показателей у пациентов с различными фенотипами гиперурикемии (данные пилотного исследования)</article-title><trans-title-group xml:lang="en"><trans-title>Comparison of anamnestic and laboratory parameters in patients with different phenotypes of hyperuricemia (data from a pilot study)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елисеев</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Eliseev</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елисеев Максим Сергеевич, к.м.н., зав. лабораторией микрокристаллических артритов</p><p>Москва</p></bio><bio xml:lang="en"><p>Eliseev Maxim S., PhD Med, head of Laboratory of Microcrystalline Arthritis</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чикина</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Chikina</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чикина Мария Николаевна, к.м.н., мл. научный сотрудник лаборатории микрокристаллических артритов</p><p>Москва</p></bio><bio xml:lang="en"><p>Chikina Maria N., PhD Med, junior researcher at Laboratory of Microcrystalline Arthritis</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьмина</surname><given-names>Я. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzmina</surname><given-names>Yа. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузьмина Янина Игоревна, мл. научный сотрудник лаборатории микрокристаллических артритов</p><p>Москва</p></bio><bio xml:lang="en"><p>Kuzmina Yаnina I., junior researcher at Laboratory of Microcrystalline Arthritis</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>03</day><month>12</month><year>2025</year></pub-date><volume>0</volume><issue>28</issue><issue-title>Ревматология в общей врачебной практике (2)</issue-title><fpage>22</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Елисеев М.С., Чикина М.Н., Кузьмина Я.И., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Елисеев М.С., Чикина М.Н., Кузьмина Я.И.</copyright-holder><copyright-holder xml:lang="en">Eliseev M.S., Chikina M.N., Kuzmina Y.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/4721">https://www.med-alphabet.com/jour/article/view/4721</self-uri><abstract><p>Бессимптомная гиперурикемия (БГУ) и подагра – патологические состояния с повышенным уровнем мочевой кислоты (МК) в крови. Подагра отличается острыми приступами артрита из-за кристаллизации МК в суставах. Вопрос о других различиях между БГУ и подагрой требует дальнейшего изучения.</p><sec><title>Цель исследования</title><p>Цель исследования: выявить ключевые различия между фенотипами ГУ.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследовано 220 пациентов с ГУ (МК &gt;360 мкмоль/л) старше 18 лет, которые были разделены на фенотипы: БГУ; БГУ с кристаллами моноурата натрия (верифицированы на УЗИ или анализом синовиальной жидкости) (БГУ+кристаллы); интермиттирующая подагра (П); тофусная подагра (П+тофусы). Сравнительная характеристика групп включала оценку частоты сопутствующих заболеваний, основных лабораторных параметров, обменные нарушения.</p></sec><sec><title>Результаты</title><p>Результаты. По результатам фенотипирования группа пациентов с БГУ составила 40 человек (18,2 %), БГУ+кристаллы – 26 (11,8 %), П – 111 (50,5%), П+тофусы – 43 (19,5). Средний возраст в группах был сопоставим (p=0,5). Выявлено нарастание частоты артериальной гипертензии (АГ) и нефролитиаза в ряду БГУ без кристаллов – БГУ+кристаллы – П – П+тофусы (p=0,0006 и p=0,00006 соответственно). Схожие закономерности были выявлены для среднего сывороточного уровня МК (p=0,00001), креатинина (p=0,0003) и ГГТ (p=0,0003), средние значения которых нарастали последовательно от БГУ до П+тофусы. Максимальные средние уровни СРБ были у пациентов с П и П+тофусы (5,3 [2,3; 12,5] мг/л), что было достоверно больше, чем у пациентов БГУ (р=0,04). СКФ была ниже в группе П+тофусы по сравнению с БГУ (74,7±20,0 мл/мин/1,73м2 vs 86,8±17,9 мл/мин/1,73м2 соответственно, p=0,02).</p></sec><sec><title>Выводы</title><p>Выводы. Частота АГ, нефролитиаза, сывороточных уровней ГГТ и креатинина нарастает по мере прогрессирования ГУ от БГУ до П+тофусы, что может быть отражением интенсивности хронического микрокристаллического воспаления.</p></sec></abstract><trans-abstract xml:lang="en"><p>Asymptomatic hyperuricemia (AHU) and gout are pathological conditions characterized by elevated uric acid (UA) levels in the blood. Gout is characterized by acute arthritis attacks due to UA crystallization in the joints. Other differences between AHU and gout require further study.</p><sec><title>Study objective</title><p>Study objective. To identify key differences between AHU phenotypes.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 220 patients with HU (UA &gt;360 μmol/L) over 18 years of age were examined and divided into the following phenotypes: AHU; AHU with monosodium urate crystals (verified by ultrasound or synovial fluid analysis) (AHU+crystals); intermittent gout (G); tophaceous gout (G+tophi). Comparative characteristics of the groups included an assessment of the frequency of comorbidities, metabolic disorders, and the main laboratory parameters.</p></sec><sec><title>Results</title><p>Results. According to phenotyping results, the group of patients with AHU included 40 people (18.2%), AHU+crystals – 26 (11.8%), G – 111 (50.5%), G+tophi – 43 (19.5). The average age in the groups was comparable (p=0.5). An increase in the frequency of hypertension and nephrolithiasis was revealed in the series AHU without crystals – AHU+crystals – G – G+tophi (p=0.0006 and p=0.00006, respectively). Similar patterns were found for the mean serum levels of UA (p=0.00001), creatinine (p=0.0003), and GGT (p=0.0003), the mean values of which increased sequentially from AHU to G+tophi. The maximum mean levels of CRP were in patients with G and G+tophi (5.3 [2.3; 12.5] mg/L), which was significantly higher than in AHU patients (p=0.04). GFR was lower in the G+tophi group compared to AHU (74.7±20.0 ml/min/1.73m2 vs 86.8±17.9 ml/min/1.73m2 , respectively, p=0.02).</p></sec><sec><title>Conclusions</title><p>Conclusions. The incidence of hypertension, nephrolithiasis, serum GGT and creatinine levels increases as HU progresses from AGU to G+tophi, which may reflect the intensity of chronic microcrystalline inflammation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>мочевая кислота</kwd><kwd>гиперурикемия</kwd><kwd>подагра</kwd><kwd>фенотип</kwd><kwd>кристаллы моноурата натрия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>uric acid</kwd><kwd>hyperuricemia</kwd><kwd>gout</kwd><kwd>phenotypes</kwd><kwd>monosodium urate crystals</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках фундаментальной научной темы «Разработка подходов к фенотипированию аутовоспалительных дегенеративных ревматических заболеваний на основе сравнительного изучения биохимических, иммунологических и генетических факторов, связанных с состоянием костной, хрящевой, мышечной и жировой тканей» N125020501433–4.</funding-statement><funding-statement xml:lang="en">The work was carried out within the framework of the fundamental scientific topic «Development of approaches to phenotyping autoinflammatory degenerative rheumatic diseases based on a comparative study of biochemical, immunological and genetic factors associated with the state of bone, cartilage, muscle and adipose tissue» No. 125020501433–4.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Perez-Ruiz F., Dalbeth N., Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015; 32 (1): 31–41. https://doi.org/10.1007/s12325-014-0175-z</mixed-citation><mixed-citation xml:lang="en">Perez-Ruiz F., Dalbeth N., Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015; 32 (1): 31–41. https://doi.org/10.1007/s12325-014-0175-z</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N., Stamp L. Hyperuricaemia and gout: time for a new staging system?. Ann Rheum Dis. 2014; 73 (9): 1598–1600. https://doi.org/10.1136/annrheumdis-2014-205304</mixed-citation><mixed-citation xml:lang="en">Dalbeth N., Stamp L. Hyperuricaemia and gout: time for a new staging system?. Ann Rheum Dis. 2014; 73 (9): 1598–1600. https://doi.org/10.1136/annrheumdis-2014-205304</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев М. С., Елисеева М. Е. Современные аспекты патогенеза и коррекции гиперурикемии, а также ассоциированных с ней состояний. Эффективная фармакотерапия. 2019; 15 (8): 32–40.</mixed-citation><mixed-citation xml:lang="en">Eliseev M.S, Eliseeva M.E. Modern Aspects of Pathogenesis and Correction of Hyperuricemia and Associated Conditions. Effektivnaya farmakoterapiya. 2019; 15 (8): 32–40. (In Russ.). https://doi.org/10.33978/2307-3586-2019-15-8-32-40</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Freedman D.S., Williamson D.F., Gunter E.W., Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995; 141 (7): 637–644. https://doi.org/10.1093/oxfordjournals.aje.a117479</mixed-citation><mixed-citation xml:lang="en">Freedman D.S., Williamson D.F., Gunter E.W., Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995; 141 (7): 637–644. https://doi.org/10.1093/oxfordjournals.aje.a117479</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Luo J., Liu X. et al. Association between change in serum uric acid and rapid decline in kidney function in China. Sci Rep. 2024; 14 (1): 25140. Published 2024 Oct 24. https://doi.org/10.1038/s41598-024-76398-7</mixed-citation><mixed-citation xml:lang="en">Li Y., Luo J., Liu X. et al. Association between change in serum uric acid and rapid decline in kidney function in China. Sci Rep. 2024; 14 (1): 25140. Published 2024 Oct 24. https://doi.org/10.1038/s41598-024-76398-7</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Liu S., Sun H., Yang S. et al. Clustering of gout-related comorbidities and their relationship with gout flares: a data-driven cluster analysis of eight comorbidities. J Endocrinol Invest. 2024; 47 (5): 1119–1128. https://doi.org/10.1007/s40618-023-02224-y</mixed-citation><mixed-citation xml:lang="en">Liu S., Sun H., Yang S. et al. Clustering of gout-related comorbidities and their relationship with gout flares: a data-driven cluster analysis of eight comorbidities. J Endocrinol Invest. 2024; 47 (5): 1119–1128. https://doi.org/10.1007/s40618-023-02224-y</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Peral-Garrido M.L., Gómez-Sabater S., Caño R. et al. Systemic inflammation in asymptomatic hyperuricaemia with sonographic crystal deposits, including a comparison with normouricaemia and gout. Rheumatology (Oxford). 2025; 64 (4): 1807–1816. https://doi.org/10.1093/rheumatology/keae533</mixed-citation><mixed-citation xml:lang="en">Peral-Garrido M.L., Gómez-Sabater S., Caño R. et al. Systemic inflammation in asymptomatic hyperuricaemia with sonographic crystal deposits, including a comparison with normouricaemia and gout. Rheumatology (Oxford). 2025; 64 (4): 1807–1816. https://doi.org/10.1093/rheumatology/keae533</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo C.F., See L.C., Luo S.F. et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010; 49 (1): 141–146. https://doi.org/10.1093/rheumatology/kep364</mixed-citation><mixed-citation xml:lang="en">Kuo C.F., See L.C., Luo S.F. et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010; 49 (1): 141–146. https://doi.org/10.1093/rheumatology/kep364</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnan E. Interaction of inflammation, hyperuricemia, and the prevalence of hypertension among adults free of metabolic syndrome: NHANES2009–2010. J Am Heart Assoc. 2014; 3 (2): e000157. Published 2014 Mar 13. https://doi.org/10.1161/JAHA.113.000157</mixed-citation><mixed-citation xml:lang="en">Krishnan E. Interaction of inflammation, hyperuricemia, and the prevalence of hypertension among adults free of metabolic syndrome: NHANES2009–2010. J Am Heart Assoc. 2014; 3 (2): e000157. Published 2014 Mar 13. https://doi.org/10.1161/JAHA.113.000157</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Maloberti A., Mengozzi A., Russo E. et al. The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation. High Blood Press Cardiovasc Prev. 2023; 30 (5): 411–425. https://doi.org/10.1007/s40292-023-00602-4</mixed-citation><mixed-citation xml:lang="en">Maloberti A., Mengozzi A., Russo E. et al. The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation. High Blood Press Cardiovasc Prev. 2023; 30 (5): 411–425. https://doi.org/10.1007/s40292-023-00602-4</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ali N., Mahmood S., Islam F. et al. Relationship between serum uric acid and hypertension: a cross-sectional study in Bangladeshi adults. Sci Rep. 2019; 9 (1): 9061. Published 2019 Jun 21. https://doi.org/10.1038/s41598-019-45680-4</mixed-citation><mixed-citation xml:lang="en">Ali N., Mahmood S., Islam F. et al. Relationship between serum uric acid and hypertension: a cross-sectional study in Bangladeshi adults. Sci Rep. 2019; 9 (1): 9061. Published 2019 Jun 21. https://doi.org/10.1038/s41598-019-45680-4</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bjornstad P., Laffel L., Lynch J. et al. Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. Diabetes Care. 2019; 42 (6): 1120–1128. https://doi.org/10.2337/dc18-2147</mixed-citation><mixed-citation xml:lang="en">Bjornstad P., Laffel L., Lynch J. et al. Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. Diabetes Care. 2019; 42 (6): 1120–1128. https://doi.org/10.2337/dc18-2147</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Held J., Schwabl C., Haschka D. et al. Major cardiovascular events in patients with cardiovascular monosodium urate deposits in atherosclerotic plaques. Rheumatology (Oxford). 2025; 64 (3): 1443–1447. https://doi.org/10.1093/rheumatology/keae240</mixed-citation><mixed-citation xml:lang="en">Held J., Schwabl C., Haschka D. et al. Major cardiovascular events in patients with cardiovascular monosodium urate deposits in atherosclerotic plaques. Rheumatology (Oxford). 2025; 64 (3): 1443–1447. https://doi.org/10.1093/rheumatology/keae240</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Маркелова Е.И., Елисеев М.С., Попкова Т.В. и др. Распространенность и факторы риска развития артериальной гипертонии у пациентов с подагрой. Научно-практическая ревматология. 2020; 58 (6): 701–707.</mixed-citation><mixed-citation xml:lang="en">Markelova E.I., Eliseev M.S., Popkova T.V. et al. Prevalence and risk factors influencing the development of arterial hypertension in patients with a gout. Rheumatology Science and Practice. 2020; 58 (6): 701–707 (In Russ.). https://doi.org/10.47360/1995-4484-2020-701-707</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sapsford M., Gamble G.D., Aati O. et al. Relationship of bone erosion with the urate and soft tissue components of the tophus in gout: a dual energy computed tomography study. Rheumatology (Oxford). 2017; 56 (1): 129–133. https://doi.org/10.1093/rheumatology/kew383</mixed-citation><mixed-citation xml:lang="en">Sapsford M., Gamble G.D., Aati O. et al. Relationship of bone erosion with the urate and soft tissue components of the tophus in gout: a dual energy computed tomography study. Rheumatology (Oxford). 2017; 56 (1): 129–133. https://doi.org/10.1093/rheumatology/kew383</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kramer H.J., Choi H.K., Atkinson K. et al. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int. 2003; 64 (3): 1022–1026. https://doi.org/10.1046/j.1523–1755.2003.t01-2-00171.x</mixed-citation><mixed-citation xml:lang="en">Kramer H.J., Choi H.K., Atkinson K. et al. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int. 2003; 64 (3): 1022–1026. https://doi.org/10.1046/j.1523–1755.2003.t01-2-00171.x</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Roughley M.J., Belcher J., Mallen C.D., Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015; 17 (1): 90. Published 2015 Apr 1. https://doi.org/10.1186/s13075-015-0610-9</mixed-citation><mixed-citation xml:lang="en">Roughley M.J., Belcher J., Mallen C.D., Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015; 17 (1): 90. Published 2015 Apr 1. https://doi.org/10.1186/s13075-015-0610-9</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S., Chang Y., Yun K. E. et al. Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. Am J Kidney Dis. 2017; 70 (2): 173–181. https://doi.org/10.1053/j.ajkd.2017.01.053</mixed-citation><mixed-citation xml:lang="en">Kim S., Chang Y., Yun K. E. et al. Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. Am J Kidney Dis. 2017; 70 (2): 173–181. https://doi.org/10.1053/j.ajkd.2017.01.053</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ramos G.K., Goldfarb D.S. Update on Uric Acid and the Kidney. Curr Rheumatol Rep. 2022; 24 (5): 132–138. https://doi.org/10.1007/s11926-022-01069-3</mixed-citation><mixed-citation xml:lang="en">Ramos G.K., Goldfarb D.S. Update on Uric Acid and the Kidney. Curr Rheumatol Rep. 2022; 24 (5): 132–138. https://doi.org/10.1007/s11926-022-01069-3</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">KC M., Leslie S.W. Uric Acid Nephrolithiasis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; October 15, 2023.</mixed-citation><mixed-citation xml:lang="en">KC M., Leslie S.W. Uric Acid Nephrolithiasis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; October 15, 2023.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bardin T., Letavernier E., Correas J.-M. The Gouty Kidney: A Reappraisal. Gout, Urate, and Crystal Deposition Disease. 2023; 1 (1): 25–36. https://doi.org/10.3390/gucdd1010004</mixed-citation><mixed-citation xml:lang="en">Bardin T., Letavernier E., Correas J.-M. The Gouty Kidney: A Reappraisal. Gout, Urate, and Crystal Deposition Disease. 2023; 1 (1): 25–36. https://doi.org/10.3390/gucdd1010004</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sellmayr M., Hernandez Petzsche M.R., Ma Q. et al. Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease. J Am Soc Nephrol. 2020; 31 (12): 2773–2792. https://doi.org/10.1681/ASN.2020040523</mixed-citation><mixed-citation xml:lang="en">Sellmayr M., Hernandez Petzsche M.R., Ma Q. et al. Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease. J Am Soc Nephrol. 2020; 31 (12): 2773–2792. https://doi.org/10.1681/ASN.2020040523</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ruggiero C., Cherubini A., Ble A. et al. Uric acid and inflammatory markers. Eur Heart J. 2006; 27 (10): 1174–1181. https://doi.org/10.1093/eurheartj/ehi879</mixed-citation><mixed-citation xml:lang="en">Ruggiero C., Cherubini A., Ble A. et al. Uric acid and inflammatory markers. Eur Heart J. 2006; 27 (10): 1174–1181. https://doi.org/10.1093/eurheartj/ehi879</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Liu W., Song H., Man S. et al. Simple metabolic markers associated with tophaceous gout. Clin Rheumatol. 2021; 40 (12): 5047–5053. https://doi.org/10.1007/s10067-021-05861-x</mixed-citation><mixed-citation xml:lang="en">Liu W., Song H., Man S. et al. Simple metabolic markers associated with tophaceous gout. Clin Rheumatol. 2021; 40 (12): 5047–5053. https://doi.org/10.1007/s10067-021-05861-x</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев М.С., Желябина О.В., Панина Е.В. Факторы, влияющие на частоту приступов артрита, у пациентов с подагрой, не получающих уратснижающую терапию (результаты пилотного ретроспективного исследования). Научно-практическая ревматология. 2024; 62 (3): 280–285.</mixed-citation><mixed-citation xml:lang="en">Eliseev M.S., Zheliabina O.V., Panina E.V. Factors affecting the frequency of arthritis attacks in patients with gout not receiving urate-lowering therapy (results of a pilot retrospective study). Rheumatology Science and Practice. 2024; 62 (3): 280–285 (In Russ.). https://doi.org/10.47360/1995-4484-2024-280-285</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
